Charles Schwab’s Insulet PODD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$91M Buy
597,871
+54,118
+10% +$9.02M 0.01% 843
2026
Q1
$114M Buy
543,753
+21,283
+4% +$5.35M 0.02% 657
2025
Q4
$149M Buy
522,470
+10,414
+2% +$3.26M 0.02% 532
2025
Q3
$158M Sell
512,056
-169,074
-25% -$53M 0.03% 485
2025
Q2
$214M Buy
681,130
+12,450
+2% +$3.59M 0.04% 379
2025
Q1
$176M Buy
668,680
+21,721
+3% +$5.88M 0.03% 420
2024
Q4
$169M Buy
646,959
+10,694
+2% +$2.69M 0.03% 438
2024
Q3
$148M Buy
636,265
+193,839
+44% +$39.8M 0.03% 469
2024
Q2
$89.3M Buy
442,426
+22,577
+5% +$4.07M 0.02% 696
2024
Q1
$72M Buy
419,849
+12,257
+3% +$2.29M 0.02% 784
2023
Q4
$88.4M Buy
407,592
+22,247
+6% +$3.82M 0.02% 619
2023
Q3
$61.5M Buy
385,345
+8,856
+2% +$1.98M 0.02% 760
2023
Q2
$109M Buy
376,489
+6,896
+2% +$2.09M 0.03% 478
2023
Q1
$118M Buy
369,593
+143,753
+64% +$42.6M 0.04% 442
2022
Q4
$66.5M Buy
225,840
+6,716
+3% +$1.85M 0.02% 645
2022
Q3
$50.3M Sell
219,124
-168,721
-44% -$42.3M 0.02% 751
2022
Q2
$84.5M Buy
387,845
+9,147
+2% +$2.08M 0.03% 519
2022
Q1
$101M Buy
378,698
+8,601
+2% +$2.11M 0.03% 514
2021
Q4
$98.5M Buy
370,097
+8,201
+2% +$2.38M 0.03% 535
2021
Q3
$103M Buy
361,896
+25,571
+8% +$7.29M 0.03% 472
2021
Q2
$92.3M Buy
336,325
+5,812
+2% +$1.58M 0.03% 527
2021
Q1
$86.2M Buy
330,513
+3,905
+1% +$1.05M 0.03% 525
2020
Q4
$83.5M Buy
326,608
+4,922
+2% +$1.22M 0.03% 500
2020
Q3
$76.1M Buy
321,686
+3,634
+1% +$765K 0.04% 447
2020
Q2
$61.8M Buy
318,052
+23,881
+8% +$4.57M 0.03% 534
2020
Q1
$48.7M Buy
294,171
+5,901
+2% +$1.08M 0.03% 535
2019
Q4
$49.4M Buy
288,270
+11,673
+4% +$1.95M 0.03% 642
2019
Q3
$45.6M Sell
276,597
-89,020
-24% -$12.5M 0.03% 638
2019
Q2
$43.6M Buy
365,617
+9,446
+3% +$968K 0.03% 639
2019
Q1
$33.9M Buy
356,171
+23,171
+7% +$1.99M 0.02% 775
2018
Q4
$26.4M Buy
333,000
+378
+0.1% +$32K 0.02% 811
2018
Q3
$35.2M Buy
332,622
+112,760
+51% +$10.6M 0.02% 737
2018
Q2
$18.8M Sell
219,862
-87,875
-29% -$7.88M 0.01% 1136
2018
Q1
$26.7M Buy
307,737
+30,807
+11% +$2.39M 0.02% 814
2017
Q4
$19.1M Buy
276,930
+10,989
+4% +$721K 0.02% 1015
2017
Q3
$14.6M Buy
265,941
+13,271
+5% +$725K 0.01% 1145
2017
Q2
$13M Buy
252,670
+8,399
+3% +$365K 0.01% 1164
2017
Q1
$10.5M Buy
244,271
+25,241
+12% +$1.08M 0.01% 1284
2016
Q4
$8.25M Buy
219,030
+11,445
+6% +$426K 0.01% 1401
2016
Q3
$8.5M Buy
207,585
+9,592
+5% +$379K 0.01% 1282
2016
Q2
$5.99M Buy
197,993
+3,570
+2% +$111K 0.01% 1450
2016
Q1
$6.45M Buy
194,423
+4,039
+2% +$127K 0.01% 1349
2015
Q4
$7.2M Buy
190,384
+24,301
+15% +$818K 0.01% 1258
2015
Q3
$4.3M Buy
166,083
+1,164
+0.7% +$35.3K 0.01% 1572
2015
Q2
$5.11M Buy
164,919
+5,093
+3% +$150K 0.01% 1532
2015
Q1
$5.33M Buy
159,826
+9,499
+6% +$321K 0.01% 1472
2014
Q4
$6.92M Sell
150,327
-15,231
-9% -$651K 0.01% 1179
2014
Q3
$6.1M Sell
165,558
-203
-0.1% -$7.41K 0.01% 1192
2014
Q2
$6.58M Buy
165,761
+22,464
+16% +$863K 0.01% 1174
2014
Q1
$6.8M Buy
143,297
+9,755
+7% +$432K 0.01% 1080
2013
Q4
$4.96M Buy
133,542
+5,227
+4% +$193K 0.01% 1263
2013
Q3
$4.77M Buy
128,315
+5,454
+4% +$183K 0.01% 1219
2013
Q2
$3.86M Buy
+122,861
New +$3.48M 0.01% 1273

Other funds holding PODD

Charles Schwab's PODD Position: Q2 2026 in Review

Charles Schwab increased its Insulet (PODD) stake by 10% in Q2 2026, buying an estimated $9.02M and bringing the position to 597,871 shares worth $91M. The position accounts for 0.01% of the portfolio, ranked #843.

Charles Schwab first reported a position in PODD in Q2 2013 and has held it in 53 quarters since. The position peaked at $214M in Q2 2025. 723 funds tracked by Wall St. Rank hold PODD as of Q2 2026.

  • Charles Schwab held 597,871 shares of Insulet worth $91M as of Q2 2026.
  • Charles Schwab bought 54,118 Insulet shares in Q2 2026, an estimated $9.02M.
  • Insulet made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #843 holding.
  • Charles Schwab first reported a position in Insulet in Q2 2013 and has held it in 53 quarters since.
  • Charles Schwab's Insulet position peaked at $214M in Q2 2025.
  • 723 funds tracked by Wall St. Rank held Insulet as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.